Tempest Therapeutics: Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
Building upon a successful end-of-Phase 2 meeting, received FDA "Study May Proceed" letter for pivotal Phase 3 trial of amezalpat (TPST-1120) combination therapy to treat first-line HCCAnnounced agree ...
Targeted Oncology1d
FDA OKs Study of Amezalpat in Frontline Liver Cancer
The FDA approved a phase 3 trial to assess amezalpat with the current standard of care in unresectable or metastatic ...
Tempest receives FDA study may proceed for Phase 3 trial of amezalpat
Tempest Therapeutics (TPST) announced that the company received a “Study May Proceed” letter from the U.S. Food and Drug ...
Yahoo Finance1d
Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
Hoffmann-La Roche Ltd. (Roche) to advance the evaluation of amezalpat in combination with atezolizumab and bevacizumab into a ...
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
REDWOOD CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS), today reported financial results for the quarter ended September 30, 2024 and ...